University of Tasmania
Browse
MRA.PDF (51.58 kB)

Technology evaluation: MRA, Chugai

Download (51.58 kB)
journal contribution
posted on 2023-05-26, 15:59 authored by Ding, C, Jones, G
Chugai, the Japanese subsidiary of Roche, is developing a humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.

History

Publication title

Current Opinion in Molecular Therapeutics

Volume

5

Article number

1

Number

1

Pagination

64-69

ISSN

1464-8431

Publication status

  • Published

Repository Status

  • Open

Usage metrics

    University Of Tasmania

    Categories

    No categories selected

    Keywords

    No keyword provided

    Licence

    In Copyright

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC